1 Day
Source:
Sharjah24
Ionis and Novartis Heart Drug Fails
Ionis Pharmaceuticals and Novartis announced the failure of their experimental drug Belacarson in late-stage clinical trials aimed at lowering levels of a cholesterol-carrying particle in heart patients. Although the drug reduced apolipoprotein levels in line with previous studies, it did not achieve the primary goal of reducing the risk of death from heart disease, heart attacks, and strokes, leading to a 6% drop in the company's stock. These results are disappointing for investors who had been anticipating data from several experimental drugs that could continue their growth and generate potential annual sales exceeding $10 billion.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)